APHINITY is a large, randomised phase III, double-blind, placebo-controlled study that compares the efficacy and safety of chemotherapy plus trastuzumab and placebo with that of chemotherapy plus trastuzumab and pertuzumab as adjuvant therapy in approximately 4800 patients with operable, HER2-positive, primary breast cancer. Pertuzumab and trastuzumab are two drugs that target and block the HER2 protein on the cancer cells.

Several recent studies have shown that dual inhibition of the HER2 receptor with two drugs is clinically more effective than using a single agent. APHINITY is testing this hypothesis, to find out if the combination of pertuzumab and trastuzumab is better than trastuzumab alone, in terms of efficacy, for patients who have had surgery for HER2 positive breast cancer. The study aims also at exploring the safety of the combination, by looking at the potential side effects on treated patients.

The results of the primary analysis were published by New England Journal of Medicine in June 2017, with further results published in the Journal of Clinical Oncology 2021. Follow-up is ongoing and further analyses will be presented later in 2022.

PUBLICTIONS ON THE APHINITY STUDY

OTHER PROJECTS

HERA

HERA

The HERA trial influenced changes in the standard of care for those with HER2-positive breast cancer. Find out more about the study design and our involvement >>

EPoS

EPoS

The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...

NordICC

NordICC

Colorectal cancer (CRC) is major burden in western countries which develops over a long time-interval from precursor lesions which exist in the colon. Colonoscopy can detect and remove the precursor lesions and may therefore be an effective intervention for the...

WORK WITH US

Frontier Science Scotland provides adaptable solutions across data management and biostatistics for clinical trials. To find out more, get in touch.

data management

biostatistics

quality